Evidence map›Paper›PMID 39364092›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2024

Development of a comprehensive open access "molecules with androgenic activity resource (MAAR)" to facilitate risk assessment of chemicals.

Fan Dong, Barry Hardy, Jie Liu, Tomaz Mohoric, Wenjing Guo, Thomas Exner, Weida Tong, Joh Dohler, Daniel Bachler, Huixiao Hong

Abstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Realizing Impact of Artificial Intelligence in Real World Enhances Public Health.Experimental biology and medicine (Maywood, N.J.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fan DongNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.
Barry HardyEdelweiss Connect Inc., Durham, NC, United States.
Jie LiuNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.
Tomaz MohoricEdelweiss Connect Inc., Durham, NC, United States.
Wenjing GuoNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.
Thomas ExnerEdelweiss Connect Inc., Durham, NC, United States.
Weida TongNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.
Joh DohlerEdelweiss Connect Inc., Durham, NC, United States.
Daniel BachlerEdelweiss Connect Inc., Durham, NC, United States.
Huixiao HongNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of endocrine-disrupting chemicals (EDCs) and their potential adverse effects on human health underscore the necessity for robust tools to assess and manage associated risks. The androgen receptor (AR) is a critical component of the endocrine system, playing a pivotal role in mediating the biological effects of androgens, which are male sex hormones. Exposure to androgen-disrupting chemicals during critical periods of development, such as fetal development or puberty, may result in adverse effects on reproductive health, including altered sexual differentiation, impaired fertility, and an increased risk of reproductive disorders. Therefore, androgenic activity data is critical for chemical risk assessment. A large amount of androgenic data has been generated using various experimental protocols. Moreover, the data are reported in different formats and in diverse sources. To facilitate utilization of androgenic activity data in chemical risk assessment, the Molecules with Androgenic Activity Resource (MAAR) was developed. MAAR is the first open-access platform designed to streamline and enhance the risk assessment of chemicals with androgenic activity. MAAR's development involved the integration of diverse data sources, including data from public databases and mining literature, to establish a reliable and versatile repository. The platform employs a user-friendly interface, enabling efficient navigation and extraction of pertinent information. MAAR is poised to advance chemical risk assessment by offering unprecedented access to information crucial for evaluating the androgenic potential of a wide array of chemicals. The open-access nature of MAAR promotes transparency and collaboration, fostering a collective effort to address the challenges posed by androgenic EDCs.

Indexed as

AndrogensEndocrine DisruptorsAnimalsDatabases, FactualHumansMaleReceptors, AndrogenRisk AssessmentAndrogensEndocrine DisruptorsReceptors, Androgenandrogen receptorchemicalsdatabaseopen accessrisk assessment

Identifiers

PMID39364092
PMCPMC11446862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.